B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin in Alcohol Use Disorder Trial at NYU and Silver Hill Hospital

Silver Hill Hospital is proud to be collaborating with B.More Inc., a non-profit, clinical-stage biopharmaceutical company dedicated to the development of psychedelic medicines for substance abuse disorders, and Dr. Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, on a significant grant from the National Institute of Alcohol Abuse and Alcoholism (NIAAA).

Patient recruitment for this study is expected to begin at Silver Hill in early 2025. 

Read the full press release here.